NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 2.30 | 0.03% |
CAC 40 | 7,715.60 | 7.87 | -0.10% |
DAX 40 | 24,084.86 | 11.19 | 0.05% |
Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
FTSE 100 | 8,811.61 | 5.08 | 0.06% |
HKSE | 24,134.74 | 246.91 | 1.03% |
NASDAQ | 20,412.52 | 188.59 | -0.92% |
Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
S&P 500 | 6,229.98 | 49.37 | -0.79% |
S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
SSE Composite Index | 3,497.48 | 24.35 | 0.70% |